scispace - formally typeset
Search or ask a question

Showing papers by "Cindy Luongo published in 2019"

Journal Article•DOI•
Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated.

[...]

Coleen K. Cunningham1, Ruth A. Karron2, Petronella Muresan3, Elizabeth J. McFarland4, Charlotte Perlowski5, Jennifer Libous5, Bhagvanji Thumar2, Devasena Gnanashanmugam6, Jack Moye6, Elizabeth Schappell2, Emily Barr4, Vivian Rexroad2, Mariam Aziz7, Jaime G. Deville8, Richard M. Rutstein9, Lijuan Yang6, Cindy Luongo6, Peter Collins6, Ursula J. Buchholz6 •
Duke University1, Johns Hopkins University2, Harvard University3, Anschutz Medical Campus4, Durham University5, National Institutes of Health6, Rush University Medical Center7, University of California, Los Angeles8, Children's Hospital of Philadelphia9
06 May 2019-Open Forum Infectious Diseases
TL;DR: RSV LIDcpΔM2-2 is overattenuated and respiratory symptoms or fever were common in vaccinees and placebo recipients, and RSV serum antibodies, vaccine infectivity, and reactogenicity were assessed.
Abstract: Background The live respiratory syncytial virus (RSV) candidate vaccine LIDcpΔM2-2 is attenuated through deletion of M2-2 and 5 cold-passage mutations. Methods RSV-seronegative children aged 6-24 months received a single intranasal dose of 105 plaque-forming units (PFU) of LIDcpΔM2-2 or placebo. RSV serum antibodies, vaccine infectivity, and reactogenicity were assessed. Results Four of 11 (36%) vaccinees shed vaccine virus with median peak titers of 1.6 log10 PFU/mL by quantitative culture and 4.5 log10 copies/mL by polymerase chain reaction; 45% had ≥4-fold rise in serum-neutralizing antibodies. Respiratory symptoms or fever were common in vaccinees (64%) and placebo recipients (6/6, 100%). Conclusions RSV LIDcpΔM2-2 is overattenuated. Clinical Trial Numbers. NCT02890381, NCT02948127.

15 citations